Harrow
Manufacturing · Tennessee, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1A Burton Hills Blvd Ste 200, Nashville,...Phone Number
(615) 733-4730Website
www.harrow.comRevenue
$275.6 MillionStock Symbol
HROWIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Harrow
Harrow, Inc. is a U.S.-based pharmaceutical company focused on developing, manufacturing, and commercializing prescription ophthalmic (eye care) products. The company specializes in medications used by ophthalmologists, optometrists, and eye-care professionals, including treatments for conditions related to cataract surgery, glaucoma, dry eye, infections, and other ocular disorders. Harrow operates primarily in the U.S. ophthalmic pharmaceutical market and focuses on expanding access to branded eye-care therapies. Harrow, Inc is headquartered in Nashville, Tennessee.Explore more
Harrow Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Harrow your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Harrow had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Harrow recently announced quarterly report
Check out if Harrow is spiking on competitors!
Funding: Get notified immidiatlly once Harrow has new funding data
Congratulate Masked Content for being promoted to Masked Content at Harrow
Check if Harrow has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Harrow launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Harrow, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Harrow
Compare insights from companies similar to Harrow, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Harrow is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Harrow is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Harrow.
Harrow financials insights
Gather financial insights about Harrow, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$1M
2023
Debt
$112.5M
Harrow Tech Stack
A closer look at the technologies used by Harrow
Most Recent Scoops
Person-Based
Events, Medical Research, Patient Experience
Open Position
Project
Harrow has announced plans to initially commercialize G-MELT in the ophthalmic surgical market, with subsequent expansion into broader procedural sedation markets including colonoscopies, MRI procedures, vasectomies, dermatology, and women's health, targeting approximately 100 million annual procedures in the US, as well as international markets including South Korea and Turkey.
Business Development
Project
Harrow has restored supply chain, expanded label-based selling including ophthalmic surgery use cases, and newly obtained CMS pass-through status enabling separate reimbursement outside the capitated fee.
Pharmaceuticals
Partnership
Harrow News & Media
Harrow Announces Second Quarter 2026 Financial Results
Second Quarter 2026 and Selected Highlights:Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the U.S., China,Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
INCHEON, Korea and NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, presented interim data from a post-marketing surveillance (PMS) study on SB11 (US brand name: BYOOVIZ®, Korea brand name: AMELIVU®), a biosimilar referencing Lucentis1, at the 44th Annual Meeting of the American Society of Retina Specialists (ASRS), held in Montréal, Canada, July 15–18, 2026.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Harrow
Sign Up For FreeTo access detailed company insights
Harrow, Inc. is a U.S.-based pharmaceutical company focused on developing, manufacturing, and commercializing prescription ophthalmic (eye care) products. The company specializes in medications used by ophthalmologists, optometrists, and eye-care professionals, including treatments for conditions related to cataract surgery, glaucoma, dry eye, infe... Read More
